Available for licensing from the National Institutes of Health is a method for large-scale production, recovery, and purification for plasmid DNA manufacturing meeting human clinical trial requirements. DNA plasmid recovery and purification methods can separate plasmid from contamination from a variety of sources, including cellular debris and proteins as well as genomic DNA and RNA.
The overall recovery of this process is greater than 400 mg of formulated final product per kilogram (wet weight) of E. coli cell paste.
This technology has potential uses in drug manufacturing and clinical studies. In the United States alone, more than 40,000 clinical trials were conducted. The potential market is worth several billion dollars.
More info: Dr. John Hewes, 301-496-0477
